Beyond
willpower.

How much weight can I realistically lose?

These are population averages — individual results depend on starting weight, dose tolerated, adherence, and the lifestyle work underneath. Most meaningful change appears in the first 6–9 months. The higher the dose you can tolerate without intolerable side effects, the greater the loss. Tirzepatide is currently best-in-class; retatrutide will likely surpass it once approved.

Will I regain the weight if I stop?

Yes, without a plan. The STEP 1 extension trial showed that participants who stopped semaglutide without structured support regained approximately two-thirds of their lost weight within a year. GLP-1 agonists don’t “cure” obesity — they manage it, like blood pressure medication manages hypertension.

That’s why TTL starts with bedrock (protein floor, resistance training, sleep, metabolic flexibility) before pharmacology. When the foundation is solid, tapering is possible for some people. For others, low-dose maintenance is the right long-term answer. Your plan models both paths.

Typical treatment duration: Most clinicians plan for 12–24 months at therapeutic dose, then reassess. Some patients taper to the lowest effective dose; some stop entirely with careful monitoring; some stay on long-term. There is no universal stop date.

What are the real side effects — and how do you manage them?

Most GI side effects are dose-dependent and improve with time. The key lever is titration speed — a slower ramp means fewer side effects, even if weight loss starts later. Your plan includes the specific signals that tell you (and your clinician) to slow down.

What about muscle loss, “Ozempic face,” and body composition?

“Ozempic face” refers to facial volume loss from rapid subcutaneous fat reduction. It’s not a direct drug side effect — it’s what fast weight loss looks like in the face, particularly in people over 40 with less collagen reserve.

Muscle loss is the real concern. In trials, roughly 25–40% of total weight lost on GLP-1 agonists alone is lean mass. Without intervention, that means weaker bones, lower metabolic rate, and a body that rebounds faster.

How to prevent it:

• Resistance training 3–4x/week (non-negotiable)
• Protein floor: 1.2–1.6 g/kg body weight daily, even when appetite is suppressed
• Creatine monohydrate (5 g/day) for additional lean-mass support
• Slower dose escalation if weight loss exceeds ~1% body weight/week
• DEXA or bioimpedance tracking every 8–12 weeks

This is why TTL’s GLP-1 lane starts with bedrock — the resistance work and protein habit are in place before the pharmacology layers on, so the loss is fat-dominant from day one.

Who should NOT take GLP-1 agonists?

These are absolute or strong relative contraindications your clinician will screen for:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)
• History of pancreatitis
• Pregnancy or actively trying to conceive (discontinue at least 2 months before conception for semaglutide; 1 month for tirzepatide)
• Severe gastroparesis or bowel obstruction
• History of eating disorders — appetite suppression can mask or worsen disordered patterns
• Type 1 diabetes (not indicated; risk of DKA complications)

Your TTL intake flags these automatically and includes them in your clinician-ready brief so nothing gets missed during the visit.

Are there benefits beyond weight loss?

Increasingly, yes — and this is where the longevity angle enters:

• Cardiovascular risk reduction. The SELECT trial (2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in overweight/obese adults without diabetes. First obesity drug to demonstrate hard CV endpoints.
• Liver health (MASH/NAFLD). GLP-1 agonists significantly reduce liver fat, inflammation markers, and fibrosis scores. Multiple Phase 3 trials are pursuing semaglutide as a MASH therapeutic.
• Systemic inflammation. Reductions in hs-CRP, IL-6, and TNF-alpha observed across trials — driven partly by fat loss and partly by direct receptor effects.
• Neuroprotection (emerging). GLP-1 receptors exist in the brain. Early trials exploring semaglutide for Alzheimer’s and Parkinson’s are underway (EVOKE, Phase 3). Not proven yet, but the signal is real.
• Kidney protection. The FLOW trial (2024) showed semaglutide reduced kidney disease progression by 24% in patients with Type 2 diabetes and CKD.

Your Codex tracks the metabolic markers (ApoB, hs-CRP, A1C, fasting insulin) that capture these benefits beyond the number on the scale.

What does it actually cost — and what about compounded versions?

On compounded GLP-1s: Compounding pharmacies can legally produce copies of FDA-approved drugs while those drugs are on the official shortage list. This is how most cash-pay telehealth clinics offer semaglutide at $150–$500/month. The tradeoff:

• No Phase 3 bioequivalence testing on the specific compounded batch
• Sterility depends on the individual pharmacy’s practices
• Once the shortage resolves, FDA can (and has announced intent to) stop compounding
• Dosing accuracy varies — some patients report inconsistent responses batch to batch

TTL doesn’t prescribe or sell compounded product. We educate you on the landscape so you make an informed choice with your clinician — eyes open to the risks and the savings.

How does dosing work?

Both semaglutide and tirzepatide use a slow titration (dose escalation) to minimize GI side effects:

Your TTL plan includes a tolerance-guided ramp: stay at each dose until side effects are manageable before stepping up. If nausea is severe, the plan flags a slower schedule (6–8 week steps) and the signals worth discussing with your clinician before the next escalation.